Rosmarinic acid as a targeted modulator of NF-κB signaling in colorectal cancer: A promising adjunct to chemotherapy.

IF 3.2 Q3 ONCOLOGY
Md Sadique Hussain, Amita Joshi Rana, Sumel Ashique, Vikash Jakhmola, Gaurav Gupta
{"title":"Rosmarinic acid as a targeted modulator of NF-κB signaling in colorectal cancer: A promising adjunct to chemotherapy.","authors":"Md Sadique Hussain, Amita Joshi Rana, Sumel Ashique, Vikash Jakhmola, Gaurav Gupta","doi":"10.5306/wjco.v16.i7.108086","DOIUrl":null,"url":null,"abstract":"<p><p>We commend the work of Liu <i>et al</i>, who provide compelling preclinical evidence that rosmarinic acid (RA), a natural dietary polyphenol, exerts potent anti-tumor effects in colorectal cancer (CRC) by selectively suppressing the NF-κB signaling pathway. The study's integrative approach-encompassing molecular docking, transcriptional analysis, and apoptosis induction-demonstrates RA's ability to inhibit key oncogenic mediators, including cyclin D1 and MYC. Notably, RA enhances the efficacy of chemotherapeutics such as 5-fluorouracil and oxaliplatin synergistically, suggesting its potential as a chemosensitizer to overcome resistance. Given RA's established safety profile and its broad spectrum of biological activities, this study provides a strong rationale for advancing RA toward translational applications in CRC management. We highlight the relevance of this work in the broader context of natural compound-based therapeutics and inflammation-driven tumor biology.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"108086"},"PeriodicalIF":3.2000,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12304994/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v16.i7.108086","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

We commend the work of Liu et al, who provide compelling preclinical evidence that rosmarinic acid (RA), a natural dietary polyphenol, exerts potent anti-tumor effects in colorectal cancer (CRC) by selectively suppressing the NF-κB signaling pathway. The study's integrative approach-encompassing molecular docking, transcriptional analysis, and apoptosis induction-demonstrates RA's ability to inhibit key oncogenic mediators, including cyclin D1 and MYC. Notably, RA enhances the efficacy of chemotherapeutics such as 5-fluorouracil and oxaliplatin synergistically, suggesting its potential as a chemosensitizer to overcome resistance. Given RA's established safety profile and its broad spectrum of biological activities, this study provides a strong rationale for advancing RA toward translational applications in CRC management. We highlight the relevance of this work in the broader context of natural compound-based therapeutics and inflammation-driven tumor biology.

迷迭香酸作为结直肠癌中NF-κB信号的靶向调节剂:一种有希望的化疗辅助药物。
我们赞扬Liu等人的工作,他们提供了令人信服的临床前证据,证明迷迭香酸(RA)是一种天然膳食多酚,通过选择性抑制NF-κB信号通路,在结直肠癌(CRC)中发挥有效的抗肿瘤作用。该研究的综合方法-包括分子对接,转录分析和细胞凋亡诱导-证明RA能够抑制关键的致癌介质,包括细胞周期蛋白D1和MYC。值得注意的是,RA可以协同提高5-氟尿嘧啶和奥沙利铂等化疗药物的疗效,这表明它有可能成为克服耐药性的化疗增敏剂。鉴于RA的安全性和广泛的生物活性,本研究为RA在CRC管理中的转化应用提供了强有力的理论依据。我们强调这项工作在基于天然化合物的治疗和炎症驱动的肿瘤生物学的更广泛背景下的相关性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
585
期刊介绍: The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信